Society for Translational Oncology

starstarstarstarstar

Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist.
www.sto-online.org TheOncologist.com

Podcasts.com RSS Feed URL

Society for Translational Oncology navigateright Episode

RET As a Target in Lung Cancer

Rearranged during transfection (RET) proto-oncogene rearrangements have been validated as an additional oncogenic driver that occurs in 1-2% of NSCLC. Prior efforts to target RET in lung cancer patients were hampered by the lack of potent and selective RET tyrosine kinase inhibitors (TKIs), necessitating the re-purposed use of multikinase inhibitors such as cabozantinib or vandetanib, which are encumbered by suboptimal efficacy and significant toxicities. Recently, novel, oral, highly potent, and selective RET TKIs—BLU-667 (pralsetinib) and LOXO-292 (selpercatinib)—have entered the clinic.

Video Overview: https://youtu.be/XkWV7eZqc8E


Jessica J. Lin, MD

Massachusetts General Hospital

STO gratefully acknowledges educational grants in partial support of this activity from:
Agios Pharmaceuticals
Amgen
Celgene Corporation
Novartis Pharmaceuticals Corp.
Pfizer Inc.